Author: Kathryn Atkins

Figure 7: Immunological effect of Nerofe and DOX: CT26 murine model showing the immunological effect of Nerofe, DOX, and their combined treatment.

Transformation of Immunosuppressive mtKRAS Tumors Into Immunostimulatory Tumors by Nerofe and Doxorubicin

July 5, 2023

“[...] we demonstrated that the combination of Nerofe and DOX exerts a synergistic effect during mCRC treatment [...]” BUFFALO, NY- July 5, 2023 – A new research paper was published… read more

Figure 1: Upon activation by the specific agonist LY500307 ERβ binds to estrogen receptor binding elements (ERE) in regulatory regions of GPR141 and ELMO1 genes and suppresses their transcription, which in turn leads to diminished RhoC activation, reduced actin-based cell migration and metastasis.

Oncotarget

ERβ as a Mediator of Estrogen Signaling in Inflammatory Breast Cancer

July 3, 2023

“The mechanism of the anti-metastatic activity of ERβ was investigated [...]” BUFFALO, NY- July 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 12,… read more

Figure 1: Mechanisms of MCL-1 inhibitor-induced MCL-1 protein upregulation, stability, and induction of apoptosis.

Oncotarget

Decoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein Stability

June 28, 2023

“Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.” BUFFALO, NY- June 28, 2023 – A new editorial… read more

Oncotarget

Ride for Roswell 2023: Team Open Access Recap

June 26, 2023

In a remarkable achievement, Oncotarget and Team Open Access contributed to an impressive total raise of $5.6 million (and the amount continues to grow) for cancer research through the Ride… read more

Oncotarget

DPDT Anticancer Activity in Human Colon Cancer HCT116 Cells

June 26, 2023

“Altogether, our results show that DPDT preferentially targets HCT116 colon cancer cells likely through DNA topoisomerase I poisoning.” BUFFALO, NY- June 26, 2023 – A new research paper was published… read more

Oncotarget

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

June 21, 2023

“[...] the experience with GITR targeting in patients may inform the development of either novel or next-generation immunotherapy approaches.” BUFFALO, NY- June 21, 2023 – A new research perspective was… read more

Figure 4: Variable changes in phosphorylation of S6 kinase 1 was observed in both cohorts. metformin

Oncotarget

Metformin’s Role in Preventing Metabolic Syndrome during Androgen Deprivation Therapy: A Phase II Study

June 20, 2023

“[...] we found no impact of the addition of metformin to [androgen deprivation] therapy on risk of metabolic syndrome associated with castration therapy and no additional anti-tumor effects.” BUFFALO, NY-… read more

Oncotarget

Oncotarget Sponsors 2023 Ride for Roswell

June 19, 2023

Oncotarget's publisher, Impact Journals, is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer… read more

Figure 1: Proposed pathway of ACSL4-mediated stimulation of quadruple negative breast cancer cells

Oncotarget

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

June 14, 2023

“ACSL4 has been demonstrated to play a pivotal role in both normal physiology as well as in a variety of disease states, including breast and other cancers.” BUFFALO, NY- June… read more

Figure 6: LP-284 is selectively lethal in cells with TC-NER deficiency. non-Hodgkin's lymphoma

Oncotarget

LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency

June 12, 2023

“[...] we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity including nanomolar potency in fifteen in vitro NHL cell lines and in vivo preclinical NHL models.” BUFFALO, NY- June… read more